"use strict";(self.webpackChunkbiopath_docs=self.webpackChunkbiopath_docs||[]).push([[5645],{1587:(n,e,i)=>{i.r(e),i.d(e,{assets:()=>a,contentTitle:()=>o,default:()=>h,frontMatter:()=>t,metadata:()=>s,toc:()=>d});const s=JSON.parse('{"id":"investment/funding-requirements","title":"Funding Requirements","description":"Overview","source":"@site/docs/investment/funding-requirements.md","sourceDirName":"investment","slug":"/investment/funding-requirements","permalink":"/docs/investment/funding-requirements","draft":false,"unlisted":false,"editUrl":"https://github.com/biopath/biopath-docs/tree/main/docs/investment/funding-requirements.md","tags":[],"version":"current","lastUpdatedBy":null,"lastUpdatedAt":null,"sidebarPosition":5,"frontMatter":{"sidebar_position":5}}');var r=i(4848),l=i(8453);const t={sidebar_position:5},o="Funding Requirements",a={},d=[{value:"Overview",id:"overview",level:2},{value:"Total Capital Requirements",id:"total-capital-requirements",level:2},{value:"5-Year Funding Plan",id:"5-year-funding-plan",level:3},{value:"Funding Timeline",id:"funding-timeline",level:3},{value:"Series A Funding Round",id:"series-a-funding-round",level:2},{value:"Funding Amount: $3.0 Million",id:"funding-amount-30-million",level:3},{value:"Use of Funds Breakdown",id:"use-of-funds-breakdown",level:4},{value:"Team Building (40% - $1.2M)",id:"team-building-40---12m",level:5},{value:"Inventory &amp; Operations (25% - $750K)",id:"inventory--operations-25---750k",level:5},{value:"Marketing &amp; Sales (20% - $600K)",id:"marketing--sales-20---600k",level:5},{value:"Technology Development (10% - $300K)",id:"technology-development-10---300k",level:5},{value:"Working Capital (5% - $150K)",id:"working-capital-5---150k",level:5},{value:"Series A Milestones",id:"series-a-milestones",level:3},{value:"12-Month Targets",id:"12-month-targets",level:4},{value:"18-Month Targets",id:"18-month-targets",level:4},{value:"Series B Funding Round",id:"series-b-funding-round",level:2},{value:"Funding Amount: $15.0 Million",id:"funding-amount-150-million",level:3},{value:"Use of Funds Breakdown",id:"use-of-funds-breakdown-1",level:4},{value:"Market Expansion (35% - $5.25M)",id:"market-expansion-35---525m",level:5},{value:"Team Scaling (25% - $3.75M)",id:"team-scaling-25---375m",level:5},{value:"Technology Development (25% - $3.75M)",id:"technology-development-25---375m",level:5},{value:"International Expansion (10% - $1.5M)",id:"international-expansion-10---15m",level:5},{value:"Working Capital (5% - $750K)",id:"working-capital-5---750k",level:5},{value:"Series B Milestones",id:"series-b-milestones",level:3},{value:"24-Month Targets",id:"24-month-targets",level:4},{value:"36-Month Targets",id:"36-month-targets",level:4},{value:"Growth Capital Round",id:"growth-capital-round",level:2},{value:"Funding Amount: $30.0 Million",id:"funding-amount-300-million",level:3},{value:"Use of Funds Breakdown",id:"use-of-funds-breakdown-2",level:4},{value:"International Expansion (40% - $12.0M)",id:"international-expansion-40---120m",level:5},{value:"Strategic Acquisitions (30% - $9.0M)",id:"strategic-acquisitions-30---90m",level:5},{value:"Technology Platform (20% - $6.0M)",id:"technology-platform-20---60m",level:5},{value:"Working Capital (10% - $3.0M)",id:"working-capital-10---30m",level:5},{value:"Growth Capital Milestones",id:"growth-capital-milestones",level:3},{value:"12-Month Targets",id:"12-month-targets-1",level:4},{value:"24-Month Targets",id:"24-month-targets-1",level:4},{value:"Investor Value Proposition",id:"investor-value-proposition",level:2},{value:"Investment Highlights",id:"investment-highlights",level:3},{value:"Market Opportunity",id:"market-opportunity",level:4},{value:"Competitive Advantages",id:"competitive-advantages",level:4},{value:"Financial Projections",id:"financial-projections",level:4},{value:"Management Team",id:"management-team",level:4},{value:"Return Projections",id:"return-projections",level:3},{value:"Series A Investors",id:"series-a-investors",level:4},{value:"Series B Investors",id:"series-b-investors",level:4},{value:"Growth Capital Investors",id:"growth-capital-investors",level:4},{value:"Risk Factors and Mitigation",id:"risk-factors-and-mitigation",level:2},{value:"Key Risks",id:"key-risks",level:3},{value:"Market Risks",id:"market-risks",level:4},{value:"Operational Risks",id:"operational-risks",level:4},{value:"Financial Risks",id:"financial-risks",level:4},{value:"Mitigation Strategies",id:"mitigation-strategies",level:3},{value:"Risk Management",id:"risk-management",level:4},{value:"Financial Controls",id:"financial-controls",level:4},{value:"Funding Sources",id:"funding-sources",level:2},{value:"Target Investor Types",id:"target-investor-types",level:3},{value:"Series A",id:"series-a",level:4},{value:"Series B",id:"series-b",level:4},{value:"Growth Capital",id:"growth-capital",level:4},{value:"Investor Criteria",id:"investor-criteria",level:3},{value:"Ideal Investor Profile",id:"ideal-investor-profile",level:4},{value:"Investment Requirements",id:"investment-requirements",level:4},{value:"Terms and Structure",id:"terms-and-structure",level:2},{value:"Investment Terms",id:"investment-terms",level:3},{value:"Series A Terms",id:"series-a-terms",level:4},{value:"Series B Terms",id:"series-b-terms",level:4},{value:"Growth Capital Terms",id:"growth-capital-terms",level:4},{value:"Governance Rights",id:"governance-rights",level:3},{value:"Investor Rights",id:"investor-rights",level:4},{value:"Protective Provisions",id:"protective-provisions",level:4},{value:"Exit Strategy",id:"exit-strategy",level:2},{value:"Exit Timeline",id:"exit-timeline",level:3},{value:"Strategic Buyers",id:"strategic-buyers",level:3},{value:"Next Steps",id:"next-steps",level:2},{value:"Immediate Actions",id:"immediate-actions",level:3},{value:"Timeline",id:"timeline",level:3},{value:"Success Metrics",id:"success-metrics",level:3}];function c(n){const e={h1:"h1",h2:"h2",h3:"h3",h4:"h4",h5:"h5",header:"header",li:"li",ol:"ol",p:"p",strong:"strong",ul:"ul",...(0,l.R)(),...n.components};return(0,r.jsxs)(r.Fragment,{children:[(0,r.jsx)(e.header,{children:(0,r.jsx)(e.h1,{id:"funding-requirements",children:"Funding Requirements"})}),"\n",(0,r.jsx)(e.h2,{id:"overview",children:"Overview"}),"\n",(0,r.jsx)(e.p,{children:"This document outlines the comprehensive funding requirements for a peptide therapy business, including capital needs, use of funds, funding timeline, and investor value proposition across multiple funding rounds."}),"\n",(0,r.jsx)(e.h2,{id:"total-capital-requirements",children:"Total Capital Requirements"}),"\n",(0,r.jsx)(e.h3,{id:"5-year-funding-plan",children:"5-Year Funding Plan"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Total Capital Needed"}),": $48 million"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Series A"}),": $3 million (Year 1)"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Series B"}),": $15 million (Year 3)"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Growth Capital"}),": $30 million (Year 4-5)"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Working Capital Line"}),": $5 million (ongoing)"]}),"\n"]}),"\n",(0,r.jsx)(e.h3,{id:"funding-timeline",children:"Funding Timeline"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Pre-Seed"}),": Completed ($500K founder/angel funding)"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Series A"}),": Q2 2024 ($3M)"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Series B"}),": Q1 2026 ($15M)"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Growth Round"}),": Q3 2027 ($30M)"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Exit"}),": 2029-2030 (Strategic sale or IPO)"]}),"\n"]}),"\n",(0,r.jsx)(e.h2,{id:"series-a-funding-round",children:"Series A Funding Round"}),"\n",(0,r.jsx)(e.h3,{id:"funding-amount-30-million",children:"Funding Amount: $3.0 Million"}),"\n",(0,r.jsx)(e.h4,{id:"use-of-funds-breakdown",children:"Use of Funds Breakdown"}),"\n",(0,r.jsx)(e.h5,{id:"team-building-40---12m",children:"Team Building (40% - $1.2M)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Key Hires"}),": CEO, CTO, VP Sales, Quality Director"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Salaries & Benefits"}),": 12-month runway for core team"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Equity Compensation"}),": Stock option pool establishment"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Advisory Board"}),": Compensation for key advisors"]}),"\n"]}),"\n",(0,r.jsx)(e.h5,{id:"inventory--operations-25---750k",children:"Inventory & Operations (25% - $750K)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Initial Inventory"}),": 6-month supply of core peptides"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Quality Systems"}),": Testing equipment and certifications"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Facility Setup"}),": Laboratory and office space"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Regulatory Compliance"}),": Legal and compliance costs"]}),"\n"]}),"\n",(0,r.jsx)(e.h5,{id:"marketing--sales-20---600k",children:"Marketing & Sales (20% - $600K)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Digital Marketing"}),": Website, SEO, content creation"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Sales Materials"}),": Brochures, samples, presentations"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Trade Shows"}),": Industry conference participation"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Customer Acquisition"}),": Initial marketing campaigns"]}),"\n"]}),"\n",(0,r.jsx)(e.h5,{id:"technology-development-10---300k",children:"Technology Development (10% - $300K)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"E-commerce Platform"}),": Online ordering system"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"CRM System"}),": Customer relationship management"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Quality Management"}),": Documentation and tracking"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Mobile Applications"}),": Customer-facing apps"]}),"\n"]}),"\n",(0,r.jsx)(e.h5,{id:"working-capital-5---150k",children:"Working Capital (5% - $150K)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Operating Expenses"}),": 3-month buffer"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Contingency Fund"}),": Unexpected expenses"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Legal & Professional"}),": Ongoing legal and accounting"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Insurance"}),": Business and product liability"]}),"\n"]}),"\n",(0,r.jsx)(e.h3,{id:"series-a-milestones",children:"Series A Milestones"}),"\n",(0,r.jsx)(e.h4,{id:"12-month-targets",children:"12-Month Targets"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Revenue"}),": $1.5M annual run rate"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Customers"}),": 150 active customers"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Team Size"}),": 8-10 employees"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Product Portfolio"}),": 15-20 core peptides"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"18-month-targets",children:"18-Month Targets"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Revenue"}),": $3M annual run rate"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Customers"}),": 300 active customers"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Geographic Expansion"}),": 3-5 additional states"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Regulatory"}),": Full compliance framework"]}),"\n"]}),"\n",(0,r.jsx)(e.h2,{id:"series-b-funding-round",children:"Series B Funding Round"}),"\n",(0,r.jsx)(e.h3,{id:"funding-amount-150-million",children:"Funding Amount: $15.0 Million"}),"\n",(0,r.jsx)(e.h4,{id:"use-of-funds-breakdown-1",children:"Use of Funds Breakdown"}),"\n",(0,r.jsx)(e.h5,{id:"market-expansion-35---525m",children:"Market Expansion (35% - $5.25M)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Geographic Growth"}),": National market expansion"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Customer Acquisition"}),": Scaled marketing campaigns"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Sales Team"}),": Regional sales representatives"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Distribution Network"}),": Logistics and fulfillment"]}),"\n"]}),"\n",(0,r.jsx)(e.h5,{id:"team-scaling-25---375m",children:"Team Scaling (25% - $3.75M)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Department Heads"}),": VP Marketing, VP Operations, CFO"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Specialized Roles"}),": Scientists, quality specialists, engineers"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"International Team"}),": Preparation for global expansion"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Training & Development"}),": Employee skill building"]}),"\n"]}),"\n",(0,r.jsx)(e.h5,{id:"technology-development-25---375m",children:"Technology Development (25% - $3.75M)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Platform Enhancement"}),": Advanced features and capabilities"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Data Analytics"}),": Business intelligence and insights"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Automation"}),": Process automation and efficiency"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Integration"}),": Third-party system connectivity"]}),"\n"]}),"\n",(0,r.jsx)(e.h5,{id:"international-expansion-10---15m",children:"International Expansion (10% - $1.5M)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Market Research"}),": International opportunity assessment"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Regulatory Preparation"}),": Global compliance framework"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Partnership Development"}),": International distributors"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Pilot Programs"}),": Test market entry"]}),"\n"]}),"\n",(0,r.jsx)(e.h5,{id:"working-capital-5---750k",children:"Working Capital (5% - $750K)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Inventory Growth"}),": Expanded product portfolio"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Operating Buffer"}),": 6-month expense coverage"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Contingency Fund"}),": Strategic opportunities"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Professional Services"}),": Legal, accounting, consulting"]}),"\n"]}),"\n",(0,r.jsx)(e.h3,{id:"series-b-milestones",children:"Series B Milestones"}),"\n",(0,r.jsx)(e.h4,{id:"24-month-targets",children:"24-Month Targets"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Revenue"}),": $18M annual run rate"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Customers"}),": 1,200 active customers"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Team Size"}),": 35-40 employees"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"International"}),": 2-3 pilot markets"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"36-month-targets",children:"36-Month Targets"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Revenue"}),": $35M annual run rate"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Customers"}),": 2,000 active customers"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Profitability"}),": Positive EBITDA"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Market Position"}),": Top 3 market player"]}),"\n"]}),"\n",(0,r.jsx)(e.h2,{id:"growth-capital-round",children:"Growth Capital Round"}),"\n",(0,r.jsx)(e.h3,{id:"funding-amount-300-million",children:"Funding Amount: $30.0 Million"}),"\n",(0,r.jsx)(e.h4,{id:"use-of-funds-breakdown-2",children:"Use of Funds Breakdown"}),"\n",(0,r.jsx)(e.h5,{id:"international-expansion-40---120m",children:"International Expansion (40% - $12.0M)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Market Entry"}),": Europe, Asia-Pacific, Latin America"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Local Operations"}),": Regional offices and teams"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Regulatory Compliance"}),": Country-specific requirements"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Marketing & Sales"}),": Localized campaigns and strategies"]}),"\n"]}),"\n",(0,r.jsx)(e.h5,{id:"strategic-acquisitions-30---90m",children:"Strategic Acquisitions (30% - $9.0M)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Complementary Companies"}),": Technology or market access"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Talent Acquisition"}),": Key personnel and expertise"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Product Portfolio"}),": Additional peptides or capabilities"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Geographic Expansion"}),": Regional market leaders"]}),"\n"]}),"\n",(0,r.jsx)(e.h5,{id:"technology-platform-20---60m",children:"Technology Platform (20% - $6.0M)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Next-Generation Platform"}),": Advanced capabilities"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"AI & Machine Learning"}),": Predictive analytics"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Mobile & Digital"}),": Enhanced user experience"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Security & Compliance"}),": Enterprise-grade systems"]}),"\n"]}),"\n",(0,r.jsx)(e.h5,{id:"working-capital-10---30m",children:"Working Capital (10% - $3.0M)"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Global Operations"}),": Multi-country inventory"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Scaling Buffer"}),": Rapid growth support"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Strategic Initiatives"}),": New opportunities"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Risk Management"}),": Contingency planning"]}),"\n"]}),"\n",(0,r.jsx)(e.h3,{id:"growth-capital-milestones",children:"Growth Capital Milestones"}),"\n",(0,r.jsx)(e.h4,{id:"12-month-targets-1",children:"12-Month Targets"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Revenue"}),": $60M annual run rate"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"International"}),": 25% of revenue"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Acquisitions"}),": 1-2 strategic acquisitions"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Team Size"}),": 75-85 employees"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"24-month-targets-1",children:"24-Month Targets"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Revenue"}),": $100M annual run rate"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Global Presence"}),": 10+ countries"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Market Leadership"}),": #1 or #2 position"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Exit Preparation"}),": IPO or strategic sale readiness"]}),"\n"]}),"\n",(0,r.jsx)(e.h2,{id:"investor-value-proposition",children:"Investor Value Proposition"}),"\n",(0,r.jsx)(e.h3,{id:"investment-highlights",children:"Investment Highlights"}),"\n",(0,r.jsx)(e.h4,{id:"market-opportunity",children:"Market Opportunity"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Large Market"}),": $50B+ global peptide market"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"High Growth"}),": 15-25% CAGR"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Early Stage"}),": Significant market share opportunity"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Regulatory Tailwinds"}),": Favorable policy environment"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"competitive-advantages",children:"Competitive Advantages"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Quality Leadership"}),": Pharmaceutical-grade standards"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Scientific Expertise"}),": Research-backed products"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Educational Platform"}),": Market development capability"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Regulatory Compliance"}),": Proactive framework"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"financial-projections",children:"Financial Projections"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Revenue Growth"}),": 200-400% annually"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Gross Margins"}),": 60-80%"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"EBITDA Margins"}),": 25-35% at scale"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Exit Valuation"}),": $500M-1B potential"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"management-team",children:"Management Team"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Experienced Leadership"}),": Healthcare and biotech backgrounds"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Advisory Board"}),": Industry experts and thought leaders"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Proven Track Record"}),": Successful company building"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Aligned Incentives"}),": Significant equity ownership"]}),"\n"]}),"\n",(0,r.jsx)(e.h3,{id:"return-projections",children:"Return Projections"}),"\n",(0,r.jsx)(e.h4,{id:"series-a-investors",children:"Series A Investors"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Investment"}),": $3M at $12M pre-money valuation"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Ownership"}),": 20% equity stake"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Exit Valuation"}),": $500M-1B"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Return Multiple"}),": 8-17x"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"IRR"}),": 35-50%"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"series-b-investors",children:"Series B Investors"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Investment"}),": $15M at $60M pre-money valuation"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Ownership"}),": 20% equity stake"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Exit Valuation"}),": $500M-1B"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Return Multiple"}),": 7-13x"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"IRR"}),": 30-45%"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"growth-capital-investors",children:"Growth Capital Investors"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Investment"}),": $30M at $150M pre-money valuation"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Ownership"}),": 17% equity stake"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Exit Valuation"}),": $500M-1B"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Return Multiple"}),": 3-6x"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"IRR"}),": 25-35%"]}),"\n"]}),"\n",(0,r.jsx)(e.h2,{id:"risk-factors-and-mitigation",children:"Risk Factors and Mitigation"}),"\n",(0,r.jsx)(e.h3,{id:"key-risks",children:"Key Risks"}),"\n",(0,r.jsx)(e.h4,{id:"market-risks",children:"Market Risks"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Regulatory Changes"}),": FDA or state policy shifts"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Competition"}),": Large pharmaceutical company entry"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Market Adoption"}),": Slower than projected growth"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Economic Downturn"}),": Reduced healthcare spending"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"operational-risks",children:"Operational Risks"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Quality Issues"}),": Product safety or efficacy problems"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Supply Chain"}),": Disruption in peptide manufacturing"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Key Personnel"}),": Loss of critical team members"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Technology"}),": Platform development challenges"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"financial-risks",children:"Financial Risks"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Funding Availability"}),": Difficulty raising future rounds"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Cash Flow"}),": Working capital management"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Customer Concentration"}),": Over-reliance on major customers"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Currency"}),": International exchange rate fluctuations"]}),"\n"]}),"\n",(0,r.jsx)(e.h3,{id:"mitigation-strategies",children:"Mitigation Strategies"}),"\n",(0,r.jsx)(e.h4,{id:"risk-management",children:"Risk Management"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Regulatory Expertise"}),": Dedicated compliance team"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Quality Systems"}),": Rigorous testing and validation"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Supplier Diversification"}),": Multiple manufacturing partners"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Team Retention"}),": Competitive compensation and equity"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"financial-controls",children:"Financial Controls"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Conservative Planning"}),": Multiple scenario modeling"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Cash Management"}),": Disciplined spending and forecasting"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Customer Diversification"}),": Broad customer base development"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Hedging Strategies"}),": Currency and commodity risk management"]}),"\n"]}),"\n",(0,r.jsx)(e.h2,{id:"funding-sources",children:"Funding Sources"}),"\n",(0,r.jsx)(e.h3,{id:"target-investor-types",children:"Target Investor Types"}),"\n",(0,r.jsx)(e.h4,{id:"series-a",children:"Series A"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Venture Capital"}),": Healthcare-focused VC firms"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Strategic Investors"}),": Pharmaceutical companies"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Angel Investors"}),": Healthcare industry executives"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Family Offices"}),": High-net-worth individuals"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"series-b",children:"Series B"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Growth Equity"}),": Expansion-stage investors"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Corporate Venture"}),": Strategic corporate investors"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Institutional"}),": Pension funds and endowments"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"International"}),": Global healthcare investors"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"growth-capital",children:"Growth Capital"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Private Equity"}),": Growth-focused PE firms"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Strategic Acquirers"}),": Potential exit candidates"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Sovereign Wealth"}),": Government investment funds"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Public Markets"}),": Pre-IPO crossover funds"]}),"\n"]}),"\n",(0,r.jsx)(e.h3,{id:"investor-criteria",children:"Investor Criteria"}),"\n",(0,r.jsx)(e.h4,{id:"ideal-investor-profile",children:"Ideal Investor Profile"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Healthcare Focus"}),": Industry expertise and network"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Growth Stage"}),": Experience with scaling companies"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Global Reach"}),": International expansion support"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Value-Add"}),": Beyond capital contribution"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"investment-requirements",children:"Investment Requirements"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Minimum Investment"}),": $500K Series A, $2M Series B+"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Board Participation"}),": Active governance involvement"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Due Diligence"}),": Comprehensive evaluation process"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Alignment"}),": Long-term value creation focus"]}),"\n"]}),"\n",(0,r.jsx)(e.h2,{id:"terms-and-structure",children:"Terms and Structure"}),"\n",(0,r.jsx)(e.h3,{id:"investment-terms",children:"Investment Terms"}),"\n",(0,r.jsx)(e.h4,{id:"series-a-terms",children:"Series A Terms"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Valuation"}),": $12M pre-money, $15M post-money"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Liquidation Preference"}),": 1x non-participating preferred"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Anti-Dilution"}),": Weighted average broad-based"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Board Composition"}),": 2 investor, 2 founder, 1 independent"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"series-b-terms",children:"Series B Terms"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Valuation"}),": $60M pre-money, $75M post-money"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Liquidation Preference"}),": 1x non-participating preferred"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Anti-Dilution"}),": Weighted average narrow-based"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Board Composition"}),": 3 investor, 2 founder, 2 independent"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"growth-capital-terms",children:"Growth Capital Terms"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Valuation"}),": $150M pre-money, $180M post-money"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Liquidation Preference"}),": 1x participating preferred"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Anti-Dilution"}),": Weighted average narrow-based"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Board Composition"}),": 4 investor, 2 founder, 3 independent"]}),"\n"]}),"\n",(0,r.jsx)(e.h3,{id:"governance-rights",children:"Governance Rights"}),"\n",(0,r.jsx)(e.h4,{id:"investor-rights",children:"Investor Rights"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Information Rights"}),": Monthly and quarterly reporting"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Inspection Rights"}),": Access to facilities and records"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Preemptive Rights"}),": Participation in future rounds"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Tag-Along Rights"}),": Sale participation rights"]}),"\n"]}),"\n",(0,r.jsx)(e.h4,{id:"protective-provisions",children:"Protective Provisions"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Major Decisions"}),": Board approval requirements"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Budget Approval"}),": Annual operating plan consent"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Key Hires"}),": Senior management approval"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Strategic Transactions"}),": M&A and partnership approval"]}),"\n"]}),"\n",(0,r.jsx)(e.h2,{id:"exit-strategy",children:"Exit Strategy"}),"\n",(0,r.jsx)(e.h3,{id:"exit-timeline",children:"Exit Timeline"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Target Timeline"}),": 5-7 years from Series A"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Exit Options"}),": Strategic acquisition or IPO"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Valuation Range"}),": $500M-1B+"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Investor Returns"}),": 25-50% IRR target"]}),"\n"]}),"\n",(0,r.jsx)(e.h3,{id:"strategic-buyers",children:"Strategic Buyers"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Pharmaceutical Companies"}),": Novartis, Pfizer, J&J"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Biotech Companies"}),": Amgen, Gilead, Biogen"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Wellness Companies"}),": Thorne, Life Extension"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Private Equity"}),": Healthcare-focused PE firms"]}),"\n"]}),"\n",(0,r.jsx)(e.h2,{id:"next-steps",children:"Next Steps"}),"\n",(0,r.jsx)(e.h3,{id:"immediate-actions",children:"Immediate Actions"}),"\n",(0,r.jsxs)(e.ol,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Investor Outreach"}),": Target investor identification and contact"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Due Diligence Preparation"}),": Data room and documentation"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Management Presentations"}),": Pitch deck and financial model"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Reference Development"}),": Customer and partner testimonials"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Legal Preparation"}),": Term sheet and investment documentation"]}),"\n"]}),"\n",(0,r.jsx)(e.h3,{id:"timeline",children:"Timeline"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Month 1"}),": Investor outreach and initial meetings"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Month 2"}),": Due diligence and management presentations"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Month 3"}),": Term sheet negotiation and legal documentation"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Month 4"}),": Closing and funding completion"]}),"\n"]}),"\n",(0,r.jsx)(e.h3,{id:"success-metrics",children:"Success Metrics"}),"\n",(0,r.jsxs)(e.ul,{children:["\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Funding Completion"}),": Full round closure within timeline"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Investor Quality"}),": Top-tier healthcare investors"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Valuation Achievement"}),": Target valuation or better"]}),"\n",(0,r.jsxs)(e.li,{children:[(0,r.jsx)(e.strong,{children:"Strategic Value"}),": Beyond capital investor contribution"]}),"\n"]})]})}function h(n={}){const{wrapper:e}={...(0,l.R)(),...n.components};return e?(0,r.jsx)(e,{...n,children:(0,r.jsx)(c,{...n})}):c(n)}},8453:(n,e,i)=>{i.d(e,{R:()=>t,x:()=>o});var s=i(6540);const r={},l=s.createContext(r);function t(n){const e=s.useContext(l);return s.useMemo(function(){return"function"==typeof n?n(e):{...e,...n}},[e,n])}function o(n){let e;return e=n.disableParentContext?"function"==typeof n.components?n.components(r):n.components||r:t(n.components),s.createElement(l.Provider,{value:e},n.children)}}}]);